The global hospital-acquired pneumonia drugs market is witnessing an upward trend as several life sciences companies are looking to raise funds for research, trials, and development. For instance, a recent news report stated that Nabriva Therapeutics has tied up with the Securities and Exchange Commission for making its first initial public stock offering. This year, Spark Therapeutics, Zynerba, and AdaptImmune also went ahead with initial public stock offerings. Nabriva Therapeutics’s new drug, Lefamulin, is in the last stage of its clinical trial and is slated to be the next big thing for treating community-acquired bacterial pneumonia.
Browse Market Research Report of Hospital Acquired Pneumonia Drugs Market: http://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html
Global H-acquired Pneumonia Drugs Market to Reach US$3.8 Billion by 2020
The global hospital-acquired pneumonia drugs market is segmented on the basis of phase and geography. The Phase III drugs include Tedizolid phosphate, Ceftazidime/Avibactum, Amikacin Inhale, Ceftolozane/Tazobactam, Synflorix vaccine, and Plazomicin. Early phase drugs include BAL30072, MEDI4893, GSK 2189242A, AR-301 or KBSA301, AR-201 (or KBRV201), AR-401 (or KBAB401), AR-101 (or KBPA101) and AR-104 (or KBPA104), IC43, V114, and ME1100. Geographically, the global hospital-acquired pneumonia drugs market is segmented into Asia Pacific, North America, Europe, and Rest of the World.
According to a recent research report published by Transparency Market Research, the global hospital-acquired pneumonia drugs market is expected to reach a valuation of US$3.8 billion by the end of 2020. This growth will be propelled by the rise in the prevalence of infections caused by multidrug-resistant organisms. These make recovering or healthy patient weaker, thereby increasing the convalescence period, which comes with unwanted medical complications.
Some of the phase III drugs still in the clinical trials are Tedizolid phosphate by Cubist Pharmaceuticals, Bayer Healthcare’s Amikacin inhale, GlaxoSmithKline’s Synflorix, AstraZeneca PLC’s Ceftazidime/avibactam, Achaogen, Inc’s Plazomicin, and Ceftolozane/tazobactam. If these drugs pass the trial, they will hit the market by 2017. The increasing number of clinical trials being conducted for biological drugs shows the shifting trend away from antibiotics.
Browse Market Research Press Release of Hospital Acquired Pneumonia Drugs Market: http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-pneumonia-drugs.htm
Developing Economies to be Largest Contributors to Global H-acquired Pneumonia Drugs Market
The biggest factor contributing to the growth of the global hospital-acquired pneumonia drugs market is the increasing prevalence of drug-resistant bacteria. In a survey conducted by the Centers for Disease Control and Prevention (CDC) revealed that about 63% of Acinetobacter variants happen to be multidrug-resistant. The most dangerous microorganism leading to deadly pneumonia is methicillin-resistant Staphylococcus aureus (MRSA).
The CDC further stated that there were 80,400 MRSA infections in 2011, of which 11,000 proved to be fatal. A factsheet presented by the World Health Organization (WHO) also showed that the occurrence of hospital-acquired pneumonia or other nosocomial infections is higher amongst low- and middle-income group in developing economies. This makes them the biggest contributors to the growth of the global hospital-acquired pneumonia drugs market and this demand pattern in the global hospital-acquired pneumonia drugs market is expected to remain consistent over the next few years.